Reference number(s)
3322-A

This document applies to the following:

Formulary	Applies
Advanced Control (ACF)	☐
Advanced Control Formulary Chart (ACFC)	☐
Advanced Control – Choice (ACCF)	☐
Basic Control (BC)	☐
Basic Control Chart (BCC)	☐
Standard Control (SF)	☐
Standard Control Formulary Chart (SFC)	☐
Standard Control – Choice (SCCF)	☐

Formulary	Applies
Value (VF)	☐
Value Formulary Chart (VFC)	☐
Managed Medicaid Template (MMT)	☐
Marketplace (MF)	☑
Aetna Small Group Affordable Care Act (SG ACA) Aetna Health Exchange (AHE)	☑
Aetna Individual Lives (IVL)	☑
Aetna-Fully Insured Advanced Control Formulary (Aetna FI ACF)	☐
Aetna Fully Insured Advanced Control Formulary Chart (Aetna FI ACFC)	☐
Aetna Fully Insured Standard Opt-Out (Aetna FI SOO)	☐

Medical Necessity Criteria
Pancreaze, Pertzye

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Pancreaze	pancrelipase
Pertzye	pancrelipase

Indications

FDA-approved Indications

© 2025 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

Pancreaze, Pertzye

These products are indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients.

Coverage Criteria

Exocrine Pancreatic Insufficiency

Authorization may be granted when the requested drug is being prescribed for the treatment of exocrine pancreatic insufficiency when the following criteria is met:

- The patient has experienced a documented intolerance to or has a clinical reason to avoid ALL of the preferred products: Creon, Viokace, and Zenpep. [ACTION REQUIRED: Documentation is required for approval.]

Continuation of Therapy

All Indications (Pediatric)

Authorization may be granted for the requested drug when the following criteria is met:

- The patient is less than 18 years of age.

Exocrine Pancreatic Insufficiency

All patients (including new patients) requesting authorization for continuation of therapy must meet ALL requirements in the coverage criteria section.

Duration of Approval (DOA)

- 3322-A: DOA: 12 months

References

1. Pancreaze [package insert]. Campbell, CA: Vivus LLC; February 2024.
2. Pertzye [package insert]. Bethlehem, PA: Digestive Care, Inc.; February 2024.

 © 2025 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

3. Lexicomp Online, Lexi-Drugs Online. Waltham, MA: UpToDate, Inc.; 2024. https://online.lexi.com. Accessed September 3, 2024.
4. Micromedex® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: https://www.micromedexsolutions.com/ (cited: 09/03/2024).

 © 2025 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.